Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Pulse Biosciences (NASDAQ: PLSE) recently announced the granting of equity inducement awards to three new employees. The Compensation Committee approved stock options for a total of 108,500 shares at an exercise price of $2.05, matching the closing stock price on June 15, 2022. The awards are structured mostly with four-year time-based vesting and include performance criteria for one employee. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent within the company.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the successful closing of its rights offering, raising $15 million by selling 7,317,072 units at $2.05 each. Each unit consists of one share of common stock and one warrant for an additional share. The rights offering attracted significant investor interest, exceeding the $15 million limit, leading to a proportionate allocation for over-subscriptions. The gross proceeds may increase to $30 million if all warrants are exercised. As of now, the company has 37,119,352 shares outstanding, effective from the offering.
Pulse Biosciences (NASDAQ: PLSE) announced preliminary results of its rights offering, which expired on May 26, 2022. The final subscription price per Unit was set at $2.05, with each Unit consisting of one common share and one warrant. The offering is expected to generate $15 million in gross proceeds, with an additional potential of $15 million from warrant exercises. Subscription rights not exercised by the expiration date have expired. The results remain preliminary pending finalization by the Subscription Agent.
Pulse Biosciences (Nasdaq: PLSE) has announced an extension for its current rights offering to May 26, 2022, allowing shareholders more time to exercise their rights. The Alternate Price for shares will be based on the volume-weighted average price over five trading days prior to May 23, 2022. This change aims to accommodate reports that some brokers set earlier cut-off dates. The subscription price remains at the lesser of $3.72 or the calculated average price, with previously issued terms still in effect. The rights offering is registered with the SEC.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported Q1 2022 revenue of $444 thousand with system revenue of $367 thousand and cycle units revenue of $77 thousand. The company transitioned 10 Controlled Launch Program participants to commercial use, leading to a total of 39 commercial conversions by quarter-end. Despite a decrease in overall utilization, new leadership has been appointed to enhance strategies. However, GAAP net loss was ($17.3 million), an improvement from ($18.6 million) the previous year, while cash reserves dropped to $12.7 million.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has initiated a rights offering to raise up to $15,000,000. Existing shareholders as of April 25, 2022 will receive non-transferable subscription rights to purchase Units, each comprising one share of Common Stock and a warrant. The initial price is set at $3.72 per Unit, but may adjust based on market conditions. The offering expires on May 23, 2022. This move is part of the company’s shelf registration statement effective since August 21, 2020.
Pulse Biosciences (NASDAQ: PLSE) will announce its financial results for Q1 2022 on May 11, 2022, after market close. A conference call will follow at 1:30 PM PT. Investors can join by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), or via a live webcast at investors.pulsebiosciences.com. The company is focused on innovative bioelectric medicine, leveraging its CellFX® System powered by Nano-Pulse Stimulation™ technology to enhance dermatologic treatments.
Pulse Biosciences (Nasdaq: PLSE) announced significant findings at the ASLMS Annual Meeting held from April 27-30, 2022, in San Diego, California. An oral presentation revealed that 12-month data for the treatment of Sebaceous Hyperplasia shows a 73% success rate in lesion clearance with good cosmetic results. A poster presentation discussed a successful case of HPV-related dermatosis treated with Nano-Pulse Stimulation (NPS). The findings highlight the clinical efficacy and safety of the CellFX® System for challenging dermatological conditions.
Pulse Biosciences, Inc. (PLSE) has announced a rights offering aimed at raising up to $15,000,000. Available to stockholders of record as of April 25, 2022, the offering will commence around May 4, 2022. Shareholders can purchase units consisting of one share of common stock and a warrant at a price based on the lesser of $3.72 or the volume-weighted average price prior to expiration on May 23, 2022. The rights offering, set to be registered with the SEC, is a strategic move to enhance liquidity and support growth initiatives.
Pulse Biosciences (Nasdaq: PLSE) announced its financial results for Q4 and full year 2021, reporting Q4 revenue of $844k and total annual revenue of $1.4 million. The company implemented leadership changes and initiated expense reduction programs to lower costs by 20%. Gross loss for Q4 was $0.4 million, with operating expenses increasing to $15 million. Full year GAAP net loss reached $63.7 million, an increase from 2020. The firm plans to enhance clinic utilization and expand the CellFX System's applications in dermatology.